We investigated the effect of the histone deacetylase inhibitors (HDIs), trichostatin A and trapoxin A on leukemia cells and cell lines from the viewpoint of differentiation induction. TSA induced differentiation in erythroid cell lines by itself, whereas it synergistically enhanced the differentiation that was directed by all-trans retinoic acid (ATRA) or vitamin D3 in U937, HL60 and NB4 cells. The combined treatment of HDI with ATRA induced differentiation in ATRA-resistant HL60 and NB4 cells. The transcriptional expression during the treatment with HDI was examined in HL60, U937 and MEG-O1. Cell cycle-regulator genes (p21 waf1 and p16 INK4A ) were upregulated or constantly expressed, erythroid-specific genes (GATA-1, ␤-globin) were silent or downregulated, and housekeeping genes (␤-actin and GAPDH) were constantly expressed. Twelve of 35 (34%) clinical samples from AML patients ranging from M0 to M7 also displayed both phenotypical and morphological changes by the treatment with TSA alone. HDIs are thus the potent inducer or enhancer of differentiation in acute myeloid leukemia and regulate transcription in an ordered manner.
Introduction
The acetylation and deacetylation of histones are regarded as the key machinery of transcriptional activation and repression, respectively.
1 p300/CBP and other coactivators such as P/CAF have histone acetyltransferase activity associated with transcription. 2 Many investigators have also shown that histone deacetylase (HDAC) interacts with inactive and/or nonliganded transcription factors via corepressors such as mSin3A, N-CoR and SMRT to repress the transcription in mammalian cells. 3 On the basis of the molecular background, HDAC inhibitors (HDIs) such as butyrate, trichostatin A (TSA) 4, 5 and trapoxin A (TPX) 6, 7 were shown to release the repression, resulting in transcription of the target genes. Recently, three independent groups [8] [9] [10] demonstrated that HDI released the repression in vitro by a fusion protein, PML-RAR␣, which is responsible for acute promyelocytic leukemia (APL). The combined therapy using all-trans retinoic acid (ATRA) and butyrate was reported to induce complete remission of ATRA-resistant APL in the clinical setting. 11 Thus HDIs are expected as promising agents for 'differentiation therapy' in APL, if used in combination with ATRA.
However, differentiation therapy has been clinically effective only when ATRA is used against APL. Differentiation therapy is theoretically applicable to all types of AML, because differentiation block is one of the most important pathophysiology in AML. 12 Recent studies elucidate that chimeric transcription factors, generated by chromosomal translocations, are frequently associated with the differentiation block. For developing a new differentiation therapy, one strategy is the Correspondence: T Naoe; Fax: 81 52 744 2801 Received 13 November 1998; accepted 28 May 1999 chimeric transcription factor-targeted therapy. In APL, ATRA targets PML-RAR␣ to modulate the function and to downregulate. However, it is difficult to find such ligands. Another way is the 'targeted transcription therapy'. Since most of the chimeric transcription factors in AML are also supposed to repress serial transcription, the combination with HDI may induce differentiation in a variety of AML.
Actually, HDIs are known to induce differentiation and/or apoptosis in many cell lines. [13] [14] [15] HDIs also caused reversion of transformed NIH3T3 cells to normal. However, few studies have investigated the possibility of applying HDI to leukemia from the viewpoint of differentiation-induction therapy. Here we have investigated the effects of the HDIs, TSA and TPX, not only on APL, but also on other subtypes of AML cells and cell lines.
Materials and methods

Cell lines and HDIs
Cell lines used in this study were cultured in RPMI 1640 medium supplemented with l-glutamine (2 mm), antibiotics and 10% FCS at 37°C in a humidified CO 2 incubator. Cultures were initiated by seeding 0.2 × 10 6 cells/ml and maintained at 0.2-1 × 10 6 cells/ml by adjusting cell concentrations with medium. To obtain an ATRA-resistant HL60 subline, HL60 was cultured in the presence of 10 −9 m ATRA, and the concentration was gradually increased. The subline, designated as HL60/RA, was established after limiting dilution. TSA was purchased from Wako Pure Chemical Industries (Osaka, Japan). TSA was dissolved in ethanol at a concentration of 500 g/ml and stored at −20°C. Trapoxin A (TPX) was a generous gift from Shionogi (Osaka, Japan). TPX was dissolved in DMSO at a concentration of 10 g/ml and stored at −20°C. Each cell line was preliminarily cultured with a serially diluted HDI, and an optimal concentration to induce differentiation without cytotoxicity was determined. Cell viability examined by the trypan-blue dye exclusion method was always more than 80% during the treatment with HDIs at the determined concentration for differentiation assays.
Clinical samples and culture
Bone marrow mononuclear cells were isolated from 35 AML patients using the Ficoll-Hypaque method, and some of them were stocked in liquid nitrogen until use. Each sample contained more than 80% blasts. Leukemia cells (10 6 cells/ml) were cultured in RPMI 1640 containing 20% FCS with TSA at the serial concentrations of 0, 20, 50, 100, 150 and 200 ng/ml. After a 3-day culture, viability was examined by the trypan-blue dye exclusion test. The nitroblue tetrazolium (NBT)-positivity of samples was determined at a maximum concentration which kept the viability over 80%. CD markers and NBT positivity were examined after 3 days from the start of culture. After a 5-day culture, benzidine assay and morphology were studied. All clinical samples used in this study were obtained with informed consent.
Differentiation assays
Differentiation was evaluated by morphological, cytochemical and immunological examinations. Morphological changes were observed in the cytospin specimens with MayGiemsa staining.
The benzidine assay was performed according to a method previously described. 16 Simultaneously the concentration of hemoglobin (Hb) was measured using the Hb assay kit (Sigma Chemicals, St Louis, MO, USA). 17 For NBT-reduction assay, cells were mixed with a solution containing 12-O-tetradecanoyl phorbol 13-acetate (Sigma) and NBT (Sigma) as described, 18 and the percentage of positive cells was evaluated by counting 500 cells. Naphthol ASD chloroacetate esterase (acetate esterase) and ␣-naphthyl butyrate esterase (butyrate esterase) staining was performed as described. 19 The following cell surface markers were analyzed by flow cytometry (FACScan; Becton Dickinson, San Jose, CA, USA): CD11b, CD11c, CD13, CD14, CD18, CD33, CD38, CD41a, CD42b and CD61 (Beckman Coulter, Miami, FL, USA). 18 
Immunofluorescent staining by anti-PML antibody
Subcellular localization of PML and PML-RAR␣ was examined by immunofluorescent staining using anti-PML antibody as previously described. 18 
Northern blot analysis
Northern blot analysis was performed as previously described. 20 For the detection of p21 waf1 transcripts, cDNA covering the coding region was isolated using reversetranscriptase polymerase chain reaction (RT-PCR). The primers used for the RT-PCR were as follows: sense primer, 5Ј-GGAAAGCTTATGTCAGAACCGGCT-3Ј, antisense primer, 5Ј-GGCCTCGAGGGGCTTCCTCTTGGA-3Ј. As indicated by underlines, the primers contained HindIII and XhoI sites, respectively, to allow ligation of the amplified fragments into a vector. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe was used as the control.
Semi-quantitative RT-PCR
Ten micrograms of total RNA isolated from each sample was reverse-transcribed using random primers and RNaseH-free reverse transcriptase (Superscript II; Gibco BRL, Gaithersburg, MD, USA). Semi-quantitative determination of PCR products was performed following procedures. Serial 1: two dilutions of the cDNA mixture from 250 ng of total RNA were applied to RT-PCR, and the optimal dilution showing quantitative relationship was chosen. The primers used for PCR were as follows: p21 waf1 : sense primer, 5Ј-GCGCCATGTCA-GAACCGGCTG-3Ј, antisense primer, 5Ј-GCAGGCTTC-CTGTGGGCGGAT-3Ј; p16
INK4A
: sense primer, 5Ј-CGAGGCAGCATGGAGCCTT-3Ј, antisense primer, 5Ј-GCATCGCGCGCACGTCCA-3Ј; GATA-1: sense primer, 5Ј-CAGGTACTCAGTGCACCAAC-3Ј, antisense primer, 5Ј-TGGTAGAGATGGGCAGTACC-3Ј; ␤-globin: sense primer, 5Ј-GTCCTTTGGGGATCTGTCCTC-3Ј, antisense primer, 5Ј-GTGGGGTGAATTCTTGCCA-3Ј; and ␤-actin: sense primer, 5Ј-AAGAGATGGCCACGGCTGCT-3Ј, antisense primer, 5Ј-TCGCTCCAACCGACTGCTGT-3Ј. PCR was performed in Thermal-Cycler 9600 (Perkin-Elmer, Norwalk, CT, USA) in the following conditions: 30 cycles of 94°C for 1 min, 55°C for 1 min and 72°C for 2 min for denaturation, annealing and extension, respectively. The PCR products were analyzed by 1% agarose gel electrophoresis.
Results
TSA induces differentiation markers in erythroid and megakaryocytic cell lines in vitro
We first examined whether TSA induces the erythroid differentiation in HEL and K562. Benzidine-positivity and total Hb contents of these cell lines were assayed after 5-day culture. TSA induced erythroid differentiation in a dose-dependent manner ( Figure 1 ). Although these cell lines are known to have the potential for megakaryocytic differentiation with TPA or other reagents, 16 CD41a, CD42b and CD61 were not upregulated by TSA in FACS analysis (data not shown).
In a megakaryocytic cell line, MEG-O1, the treatment with 100 ng/ml TSA for 2 days increased CD41a expression from 16.4% to 58.9% and CD61 expression from 23.0% to 63.1%. However, neither polyploidy nor morphological change was obtained.
TSA enhances differentiation of a myelomonocytic leukemia cell line in vitro
Myelomonocytic differentiation 21 was studied in U937 ( Figure  2 ). The FACS analysis showed that the treatment with TSA upregulated CD11b and CD11c but did not change CD13, CD14 and CD33 (data not shown). Furthermore, a cytochemical change was not observed, suggesting that TSA alone was insufficient for differentiation.
U937 was then treated with ATRA or vitamin D3 (Vit D3) for 5 days. Neither ATRA nor Vit D3 at 10 −9 m did not change the NBT positivity. Esterase activity was not significantly induced.
Combination of TSA (75 ng/ml) with ATRA (10 −9 m) increased the NBT positivity from 0% to 22% and induced acetate esterase activity. Morphologically, nuclei of U937 were indented by the combination. On the other hand, the combination of TSA (75 ng/ml) with Vit D3 (10 −9 m) augmented the NBT positivity from 0% to 32% and induced butyrate esterase positivity from 2% to 20%. U937 showed large cytoplasm with clear vacuoles. These results suggest that TSA did not determine the direction of differentiation but enhanced the differentiation directed by ATRA or Vit D3.
21
Figure 2
Synergistic effect of differentiation in U937 cells with TSA and ATRA. May-Giemsa staining and naphthol ASD chloroacetate esterase (acetate esterase) and ␣-naphthyl butyrate esterase (butyrate esterase) double staining were performed after 5 days of treatment and 3 days of treatment, respectively. Single treatment with either 10 −9 m of ATRA, 10 −9 m of Vit D3 or 75 ng/ml of TSA caused neither significant morphological changes nor induction of esterase activity. Combined treatment of ATRA and TSA induced acetate esterase activity as well as morphological changes (lower middle). Combination of TSA with Vit D3 induced butyrate-esterase activity (lower right).
HDI overcomes the ATRA-resistance in HL60 and NB4
To further elucidate the effects of HDIs on the induction of differentiation, we analyzed two ATRA-sensitive myeloid cell lines and their ATRA-resistant sublines. We established an ATRA-resistant subline of HL60, designated as HL60/RA, which showed no growth suppression and no differentiation in the presence of 10 −6 m ATRA. A point mutation of AF2 domain of the RAR␣ gene, which is the transcription activation domain by ATRA, was confirmed by sequencing (unpublished data). We examined the effects of HDIs on a pair of HL60 and HL60/RA. Treatment with either TSA or TPX alone had a tendency to increase the NBT positivity, not only in HL60 but also in HL60/RA in a dose-dependent manner, which was not significant (Figure 3a and b) . TSA or TPX increased NBT positivity synergistically in combination with ATRA. TPX was more potent than TSA to increase NBT positivity (Figure 3c and d) .
We next examined the effects of HDIs on NB4, a promyelocytic leukemia cell line. Synergistic effects of TSA or TPX with ATRA on myeloid differentiation was observed in parental NB4 and its ATRA-resistant subline, NB4/RA 18 ( Figure 4a-d) . NBT positivity was not induced by TSA or TPX alone in either cell line. In NB4, a synergistic effect was observed in the combination of each HDI with ATRA (Figure 4a and b) . In NB4/RA, the combination of TPX with ATRA induced the NBT positivity to 20%, whereas that of TSA did not (Figure 4c and  d) . This finding suggests that TSA and TPX may act differently on the differentiation of NB4.
Immunofluorescent staining shows that in NB4, PML and PML-RAR␣ are aberrantly localized as a microgranular pat-
Figure 3
Differentiation of HL60 and its ATRA-resistant subline, HL60/RA. NBT-reduction assay was performed after 3 days of treatment with various concentrations of TSA (a and c) or TPX (b and d) in the presence or absence of ATRA. TPX had stronger synergistic effects than TSA both in HL60 and in HL60/RA. tern, which is restored to the speckled one by the treatment with ATRA. This subcellular restoration of PML staining has been thought to be associated with ATRA sensitivity. 18 However, the PML staining pattern was not changed in NB4/RA treated either with ATRA alone or with the combination of TPX with ATRA ( Figure 5 ).
Gene expression patterns during the treatment with TSA are in an ordered manner
Although HDI presumably releases the repression of transcription, little is known about the target genes. It is of particular interest to know whether the repression release by HDI occurs in selected genes or ubiquitously. We examined the expression patterns of cell cycle regulator genes (p21 waf1 and p16 INK4A ), erythroid-specific genes (GATA-1 and ␤-globin), and housekeeping genes (␤-actin and GAPDH). Northern blot analysis revealed that in U937 and HL60, p21 waf1 gene expression was remarkably increased after 3-h treatment, whereas the GAPDH gene expression was not changed (Figure 6a ).
Next we tried to detect p16 INK4A , ␤-globin and GATA-1 mRNA but the transcripts were undetectable by Northern blots. Thus semi-quantitative RT-CPR was performed in U937, HL60, and MEG-O1 treated with TSA (Figure 6b ). In these cell lines, p21 waf1 mRNA was upregulated within 1 h of treatment, which corresponded to the above Northern blots. The p16 INK4A transcripts were constantly expressed throughout the treatment in HL60 and MEG-O1, whereas it was upregulated in U937. GATA-1 and ␤-globin transcripts remained undetectable in U937 and HL60. They were downregulated after 12 h of treatment with TSA in MEG-O1 cells. 22, 23 One of the housekeeping genes, ␤-actin, was constantly transcribed throughout the treatment, which was similar to the GAPDH gene expression described above.
Primary leukemia blasts respond to TSA in vitro
We examined whether the treatment with TSA in vitro induced differentiation in primary leukemia cells from 35 AML patients. Compared with leukemia cells cultured without TSA, differentiation was estimated by morphological changes and by the following differentiation markers: increased CD11b and decreased CD33 expression in M0 to M3 (FAB classification 24 ), increased NBT positivity in M0 to M5, increased benzidine positivity in M6, and increased CD41a Differentiation of NB4 and its ATRA-resistant subline, NB4/RA. NBT-reduction assay was performed after 3 days of treatment with various concentrations of TSA or TPX in the presence or absence of ATRA. TPX had synergistic effects in NB4 (b) and NB4/RA (d), whereas the combination of TSA with ATRA showed no increase of NBT-positivity in NB4/RA (d).
Figure 5
Immunofluorescent staining by anti-PML antibody in NB4 and NB4/RA. ATRA treatment changed the POD pattern after 48 h in NB4 (lower left). NB4/RA treated without or with TSA (100 ng/ml) and/or TPX (1.2 ng/ml) in the presence or absence of ATRA (10 −6 m) were examined. Although combined treatment of TPX (1.2 ng/ml) and ATRA (10 −6 m) induced differentiation in NB4/RA, the POD pattern was not changed even after 72 h of treatment (lower right). and CD42b expression in M7. The results are summarized in Table 1 .
We tentatively decided that differentiation markers with increase or decrease of 20% or higher was significant. Thirteen of 28 cases (46%) displayed an increase in NBT positivity, eight of 10 cases displayed a decrease in CD33 expression, and two of four cases showed increase of CD11b expression. Four of five cases with M6 showed significant increase of benzidine positivity. CD41a expression was increased in one of two cases with M7. Taken together, either of the differentiation markers significantly changed in 20 of 35 cases (57%) with AML.
Morphological changes were determined if metamyelocytes, more mature granulocytes and monocytes were observed in 20% or more of the cultured cells. These changes were observed in 12 of the 28 cases (37%) from M0 to M5. These morphological changes significantly related to the increase of the NBT positivity (P = 0.01, by Fisher's exact test). In M3 and M4/5 subtypes, furthermore, nine of the 18 cases (50%) showed both significant increase of NBT positivity and morphological changes in response to TSA.
Figure 6
Transcripts expression in U937, HL60 and MEG-O1 during TSA treatment. U937, HL60 and MEG-O1 were treated with TSA at the concentrations of 75 ng/ml, 50 ng/ml and 100 ng/ml, respectively. (a) Northern blots of p21 waf1 and GAPDH transcripts. Five g of mRNA was applied to each lane. In U937 and HL60, p21 waf1 transcripts were remarkably increased by TSA treatment, while GAPDH transcripts were not changed. (b) Semi-quantitative RT-PCR of p21 waf1 , p16
INK4A , GATA-1, ␤-globin, and ␤-actin transcripts. p21 waf1 transcripts were increased by 1 h of treatment with TSA. p16
INK4A transcripts were constantly expressed in HL60 and MEG-O1, whereas they were upregulated in U937. ␤-globin and GATA-1 transcripts were downregulated after TSA treatment in MEG-O1. Expression of ␤-actin was not affected by TSA treatment in the three cell lines.
Discussion
In this study, we have demonstrated that differentiation is induced by HDI not only in leukemia cell lines but also in clinical samples from AML. We have also shown that the combination of HDI with ATRA or Vit D3 synergistically differentiates myeloid cell lines and overcomes ATRA resistance. We have further revealed that gene expression patterns during the treatment with HDI are in an ordered manner.
In two erythroid cell lines, the treatment with TSA alone upregulated Hb production. 17 On the other hand, TSA alone was insufficient to induce differentiation in myeloid cell lines, although expression of some CD markers such as CD11b was increased. Combination with ATRA or Vit D3 synergistically induced NBT positivity, esterase activity as well as morphological changes, which direction was determined by ATRA or Vit D3. 21 From these findings, we suppose that HDIs might enhance rather than initiate differentiation.
The change of PML oncogenic domain (POD) pattern in ATRA-treated NB4 is thought to reflect the proteolysis of PML-RAR␣ through the proteasome pathway. 25 Thus, the unchanged POD pattern in NB4/RA treated with both TPX and ATRA may imply the possibility that NB4/RA differentiated through an alternative pathway. HDIs might release the transcriptional repression caused by the fusion protein. It was also demonstrated that high concentration of ATRA dissociates HDAC-corepressor complex from PML-RAR␣. HDIs can cancel the HDAC effect without dissociating the HDAC-corepressor complex in vitro. 9, 10 This mechanism may contribute to the differentiation of NB4/RA.
One important finding in this study is the ordered gene expression in HDI-treated cell lines. p21 waf1 gene expression, which is closely associated with the differentiation of myeloid [26] [27] [28] [29] and megakaryocytic 30 cells, was rapidly induced by the treatment with TSA. Although this mechanism is unknown. SP1 sites of the p21 waf1 gene promoter are reportedly important for HDIs to transactivate the gene. INK4A gene was transcribed after the treatment with TSA in U937, whereas it was constantly expressed in HL60 and MEG-O1. 32, 33 The p16 INK4A gene is methylated in U937 but not in HL60 and MEG-O1 and is not transcribed in U937. Since the treatment with HDIs caused the p16 INK4A gene expression, it is of interest whether this gene is methylated or not in HDItreated U937. Recently a functional relationship between DNA methylation and histone deacetylation has been reported. 34 Further studies should be necessary. In MEG-O1, the expression of GATA-1 22 and ␤-globin 23 was suppressed after 6 h of treatment with HDI, which seemed to be a secondary event in the differentiation process. These results indicate that HDI treatment causes gene activation in an orderly and sequential manner. Our results are supported by the report that limited genes were affected by HDI as revealed by differential display analysis. 35 Why do HDIs induce particular gene expression that is associated with G1 arrest and/or differentiation? One possibility is the difference of HDI sensitivity due to the chromatin Thirty-five clinical samples from AML patients ranging from M0 to M7 (FAB classification) were examined. All the samples from M0 to M5 were cultured with TSA at 0, 20, 50, 100, 150 and 200 ng/ml for 3 days and viability was titrated. NBT-reducing activity and FACS analysis was assayed for the samples with the maximum concentration of TSA showing more than 80% of viability. For M6 samples, viability was examined at day 3 and 5, benzidine positivity and morphological change was examined at day 5 for the samples showing more than 80% cell viability. For M7 samples, viability was examined at day 3 and FACS analysis was performed simultaneously. Morphological change was examined at day 5 for all specimens. Morphological change with 20% or more mature metamyelocytes or monocytes than the control culture. In total of the 28 samples of M0 to M5, 12 samples (37%) showed significant change with both differentiation markers and morphological change. structure, which is regulated by multi-steps. The second is the different specificity of HDIs to HDAC family members. So far, three HDAC members have been identified in mammalians, five in yeast, and the functional difference of each HDAC member was indicated. 36 The third is that HDIs regulate transcription through proteins other than histones. There are several studies on post-translational acetylation of transcription factors. For example, p53 is regulated in its DNA-binding activity by acetylation/deacetylation of C-terminal portion. 37 EKLF, a transcription factor important for erythropoiesis, is also acetylated in an active form. 38 The precise mechanism of HDI-induced differentiation should be elucidated in future.
This is the first report that leukemia samples from patients respond to HDI in vitro. In M3 and M4/5 subtypes, half of the samples showed both significant increase of NBT positivity and morphological changes. However, it remains unknown whether HDIs induce differentiation in vivo. Recently new members of the HDI family have been identified by several investigators. [39] [40] [41] Among them, FR901228 42 and MS-27-275 43 can be administered in vivo and showed marked antitumor effects. Thus it seems to be possible to use HDIs in combinations with other differentiating agents as well as with conventional chemotherapy. The differentiation induction of cancer cells other than hematopoietic malignancies may also be achieved by HDIs.
